Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT02516241
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
- NCT02516241 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built an HCP commentary report on NCT02516241 (durvalumab plus tremelimumab; durvalumab in previously untreated unresectable stage IV urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02516241 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Urothelial Cancer
- Interventions
- MEDI4736 (Durvalumab); Tremelimumab; Cisplatin; Carboplatin; Gemcitabine
- Arms
- Combination Therapy · Experimental
- Monotherapy · Experimental
- Standard of Care · Active comparator
- Enrollment
- 1,126
- Primary outcomes
- To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set
- To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set
- Sponsor
- AstraZeneca
- Start
- Nov 2, 2015
- Primary completion
- Jan 27, 2020
- Results posted
- Yes
- Registry record
- NCT02516241 · updated Jul 14, 2026
Publications
linked from the registry- Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bogemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suarez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. PubMed 32971005